News coverage about Kite Pharma (NASDAQ:KITE) has been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm identifies positive and negative press coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Kite Pharma earned a daily sentiment score of 0.14 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.0667036515141 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.
Shares of Kite Pharma (NASDAQ:KITE) remained flat at $$179.79 during trading on Tuesday. Kite Pharma has a 12-month low of $39.82 and a 12-month high of $179.95. The firm has a market cap of $10,280.00 and a P/E ratio of -26.06.
ILLEGAL ACTIVITY NOTICE: This story was first published by Community Financial News and is owned by of Community Financial News. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://www.com-unik.info/2018/02/06/kite-pharma-kite-earning-somewhat-positive-press-coverage-analysis-shows.html.
Kite Pharma, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient’s T cells outside the patient’s body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient.
Receive News & Ratings for Kite Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kite Pharma and related companies with MarketBeat.com's FREE daily email newsletter.